The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Pharmacodynamic Effects of Different Aspirin Dosing Regimens in Type 2 Diabetes Mellitus Patients With Coronary Artery Disease
Abstract
Background—: Patients with type 2 diabetes mellitus (T2DM) have reduced aspirin-induced pharmacodynamic effects. This may be attributed to increased platelet turnover rates resulting in an increased proportion of non–aspirin-inhibited platelets during the daily dosing interval. The hypothesis of this study was that an increase in the frequency of drug administration [twice daily (bid) versus once daily (od)] may provide more effective platelet inhibition in T2DM patients. Methods and Results—: T2DM patients with stable coronary artery disease were prospectively recruited. Patients modified their aspirin regimen on a weekly basis according to the following scheme: 81 mg/od, 81 mg/bid, 162 mg/od, 162 mg/bid, and 325 mg/od. Pharmacodynamic assessments included light-transmittance aggregometry after arachidonic acid, collagen and adenosine diphosphate stimuli; VerifyNow-Aspirin assay; and serum thromboxane B 2 (TXB 2 ) levels. Twenty patients were analyzed. All patients were sensitive and compliant to aspirin irrespective of dose, as assessed by arachidonic acid–induced aggregation. When aspirin was administered once daily, there was no significant effect on platelet reactivity by increasing the once-daily dosing using aspirin-sensitive assays (collagen-induced aggregation and VerifyNow-Aspirin). An increase in aspirin dose by means of a second daily administration was associated with a significant reduction in platelet reactivity assessed by collagen-induced aggregation and VerifyNow-Aspirin between 81 mg/od and 81 mg/bid ( P <0.05 for both assays) and between 81 mg/od and 162 mg/bid ( P <0.05 for both assays). There was no impact of aspirin dosing regimens on adenosine diphosphate–induced aggregation. A dose-dependent effect of aspirin was observed on serum TXB 2 levels ( P =0.003). Conclusions—: Aspirin dosing regimens are associated with different pharmacodynamic effects in platelets from T2DM patients and stable coronary artery disease, with a twice-daily, low-dose aspirin administration resulting in greater platelet inhibition than once-daily administration as assessed by aspirin-sensitive assays and a dose-dependent effect on serum TXB 2 levels. The clinical implications of a modified aspirin regimen tailored to T2DM patients warrant further investigation. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01201785.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thromboxane Biosynthesis and Platelet Function in Type II Diabetes Mellitus
Davì, G., Catalano, I., Averna, M., Notarbartolo, A., Strano, A., Ciabattoni, G., & Patrono, C. (1990) · New England Journal of Medicine · doi:10.1056/nejm199006213222503 · Cited by 597
Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus
Bhatt, D. L., Marso, S. P., Hirsch, A. T., Ringleb, P. A., Hacke, W., & Topol, E. J. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02567-5 · Cited by 409
Cited by
Authors/Task Force Members, Steg, P. G., James, S. K., Atar, D., Badano, L. P., Lundqvist, C. B., Borger, M. A., Di Mario, C., Dickstein, K., Ducrocq, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs215 · Cited by 6,829
Joseph, J. J., Deedwania, P., Acharya, T., Aguilar, D., Bhatt, D. L., Chyun, D. A., Di Palo, K. E., Golden, S. H., Sperling, L. S., & on behalf of the American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, T. A. V. B. C. O. C. C. A. C. O. H. (2022) · Circulation · doi:10.1161/cir.0000000000001040 · Cited by 660
Ibánez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2017) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2017.11.010 · Cited by 461
ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy
Capodanno, D., Alfonso, F., Levine, G. N., Valgimigli, M., & Angiolillo, D. J. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.09.057 · Cited by 366
Self-citationRothwell, P. M., Cook, N. R., Gaziano, J. M., Price, J. F., Belch, J. F. F., Roncaglioni, M. C., Morimoto, T., & Mehta, Z. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31133-4 · Cited by 353
Novel antiplatelet agents in acute coronary syndrome
Franchi, F., & Angiolillo, D. J. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.156 · Cited by 353
Self-citationArnold, S. V., Bhatt, D. L., Barsness, G. W., Beatty, A. L., Deedwania, P. C., Inzucchi, S. E., Kosiborod, M., Leiter, L. A., Lipska, K. J., Newman, J. D., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000766 · Cited by 304
Mega, J. L., & Simon, T. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60243-4 · Cited by 284
ROCCA, B., SANTILLI, F., PITOCCO, D., MUCCI, L., PETRUCCI, G., VITACOLONNA, E., LATTANZIO, S., MATTOSCIO, D., ZACCARDI, F., LIANI, R., et al. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2012.04723.x · Cited by 256
Angiolillo, D. J., Jakubowski, J. A., Ferreiro, J. L., Tello-Montoliu, A., Rollini, F., Franchi, F., Ueno, M., Darlington, A., Desai, B., Moser, B. A., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.06.1170 · Cited by 182
Self-citationAngiolillo, D. J., Baber, U., Sartori, S., Briguori, C., Dangas, G., Cohen, D. J., Mehta, S. R., Gibson, C. M., Chandiramani, R., Huber, K., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.008 · Cited by 87
Self-citationBethel, M. A., Harrison, P., Sourij, H., Sun, Y., Tucker, L., Kennedy, I., White, S., Hill, L., Oulhaj, A., Coleman, R. L., et al. (2016) · Diabetic Medicine · doi:10.1111/dme.12828 · Cited by 61
Metadata
- Authors
- Capodanno, D., Patel, A., Dharmashankar, K., Ferreiro, J. L., Ueno, M., Kodali, M., Tomasello, S. D., Capranzano, P., Seecheran, N., Darlington, A., Tello-Montoliu, A., Desai, B., Bass, T. A., & Angiolillo, D. J.
- Venue
- Circulation: Cardiovascular Interventions
- Published
- 2011-04
- Volume
- 4
- Issue
- 2
- Pages
- 180-187
- ISSN
- 1941-7632 (ISSN-L)
- 1941-7640
- OpenAlex
- W2166196321
- Cited by
- 187
- References
- 2
- FWCI
- 15.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.